Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...
Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.
Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...
Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...
Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...
Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...
Recent real-world study findings have identified a potential unmet need for an effective early treatment with minimal ...
Baker, a patient and patient advocate based in the United Kingdom, received a diagnosis of essential thrombocythemia (ET) in ...
The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...
Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...
A breast cancer survivor finds support and friendship through an online group, easing her journey post-diagnosis. The ...
GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback